目的 探讨百蕊颗粒联合异丙托溴铵治疗喘息性支气管炎患儿的临床疗效。方法 选择2023年1月—2024年1月济南市妇幼保健院收治的150例喘息性支气管炎患儿进行回顾性分析，根据治疗方案不同将患者分为对照组和治疗组，每组各75例。对照组雾化吸入吸入用异丙托溴铵溶液，每日3次，每次1 mL。治疗组在对照组基础上联合百蕊颗粒，2.5 g/次，3次/d。两组均连续治疗1周。对比两组临床疗效、临床症状消退时间、血清指标[超敏C反应蛋白（hs-CRP）、铁蛋白（SF）、降钙素原（PCT）、白细胞介素-6（IL-6）]、肺功能指标[第1秒用力呼气容积（FEV1）、用力肺活量（FVC）、FEV1/FVC]。结果 治疗后，治疗组总有效率（100.00%）显著高于对照组（89.33%）（P＜0.05）。治疗组咳嗽咳痰消退时间、喘息气急消退时间、发热消退时间及肺部啰音消退时间均短于对照组（P＜0.05）。治疗后，两组患者hs-CRP、PCT、SF、IL-6均较同组治疗前显著下降（P＜0.05），治疗后治疗组Hs-CRP、PCT、SF、IL-6水平低于对照组（P＜0.05）。治疗后两组患者FVC、FEV1及FEV1/FVC值均较同组治疗前显著提高（P＜0.05）；治疗后治疗组FVC、FEV1及FEV1/FVC高于对照组（P＜0.05）。结论 百蕊颗粒联合异丙托溴铵治疗小儿喘息性支气管炎能协同增强疗效，促进临床症状消退，并有效抑制炎症反应。

Objective To explore the effect of Bairui Granules combined with ipratropium bromide in treatment of asthmatic bronchitis in children. Methods A retrospective analysis was conducted on 150 children with asthmatic bronchitis who were admitted to Jinan Maternity and Child Care Hospital from January 2023 to January 2024. Children were divided into control group and treatment group based on different treatment plans, with 75 cases in each group. Children in control group were given Ipratropium Bromide Solution for Inhalation by atomization, three times daily, 1 mL each time. Children in treatment group were given Bairui Granules in addition to control group, 2.5 g/time, 3 times daily. Both groups were treated continuously for one week. The clinical efficacy, the time for clinical symptoms to subside, the serum indicators (hs-CRP, SF, PCT, IL-6), and the pulmonary function indicators (FEV1, FVC, FEV1/FVC) were compared. Results After treatment, the total effective rate of treatment group (100.00%) was significantly higher than that of control group (89.33%), (P < 0.05). The time for cough and expectoration to subside, the time for wheezing and shortness of breath to subside, the time for fever to subside, and the time for pulmonary rales to subside in treatment group were all shorter than those in control group (P < 0.05). After treatment, the levels of hs-CRP, PCT, SF, and IL-6 in both groups decreased significantly compared to those before treatment in the same group (P < 0.05). After treatment, the levels of hs-CRP, PCT, SF, and IL-6 in treatment group were lower than those in control group (P < 0.05). After treatment, the values of FVC, FEV1, and FEV1/FVC in both groups were significantly higher than those before treatment in the same group (P < 0.05). The level of FVC, FEV1, and FEV1/FVC in treatment group were higher than those in control group (P < 0.05). Conclusion The combination of Bairui Granules and ipratropium bromide in treatment of asthmatic bronchitis in children can synergistically enhance the therapeutic effect, promote the resolution of clinical symptoms, and effectively inhibit inflammatory responses.

R974

济南市卫健委第二批委科技计划项目(2020-4-74)